COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?

NCT ID: NCT04444687

Last Updated: 2022-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-31

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at answering the question if aerosols from laparoscopic or open abdominal surgery contain SARS-CoV-2 virus and need to be considered contagious.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CoVID-19 pandemic has led to wide spread shut down of surgical services and restrictions to emergency procedures in most European countries and the United States. Next to concerns about resource limitations this has been justified by the risk of viral transmission during surgery. As to date the virus has been isolated from several body fluids with highest viral loads in the respiratory tract but also in feces. Aerosol producing interventions such as intubation have been proven to be a common source of health care worker infections in Italy and recently in the United Kingdom and the United States. The risk of surgical smoke and steam in open and laparoscopic surgery has been considered to bear similar risk but no data concerning these aerosols has been published so far and to the knowledge of the investigators no trials are under way (www.clinicaltrials.gov 5.4.2020). Only limited data has been available for other viral infections such as Hepatitis B and Human Papilloma Virus showing that surgical aerosols have the potential to carry such infectious particles. This rational has led to conflicting recommendations by surgical societies such as the Royal College of Surgeons or the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) to avoid laparoscopic procedures or use special filtration systems to evacuate the smoke and aerosols from the body cavity.

Since Switzerland and the city of Basel in particular currently have a high prevalence for CoVID 19 it is likely that surgeons will encounter patients with proven or suspected infection in the near future that require open or laparoscopic emergency surgical procedures. This offers the opportunity to collect a reasonable number of samples and smears from the abdominal cavity and surgical aerosols from these patients in limited time to answer the urgent question whether surgical smoke and aerosols of the abdominal cavity from CoVID-19 patients are contagious or not.

Investigators consider the trial to be a risk category A according to art 7 (HRO). There is no risk for patients included in this trial since the treatment of the patients will not differ from standard care. There will be no extra tests performed and only routine data will be collected. Specimen from laparoscopic smoke filters which are a protection device for medical staff will be tested on SARS-CoV-2 contamination.

Primary Objective:

The primary objective of the study is to investigate the contamination of surgical smoke and aerosols with SARS-COV-2 virus particles using the viral genome as a marker during laparoscopic and open abdominal emergency procedures for patients with suspected or proven infection.

Secondary objectives are to:

* assess the viral load in the peritoneal cavity and fluid
* compare viral load of smoke and aerosols in laparoscopic and open procedures
* assess possible transmission to surgeons during their service

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SARS-CoV-2-positive 01

SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable

Test for SARS-CoV-2

Intervention Type DIAGNOSTIC_TEST

* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR

1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

SARS-CoV-2-positive 02

SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable

Test for SARS-CoV-2

Intervention Type DIAGNOSTIC_TEST

* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR

1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

SARS-CoV-2-positive 03

SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable

Test for SARS-CoV-2

Intervention Type DIAGNOSTIC_TEST

* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR

1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

Control

Control patients, SARS-CoV-2-negative

Test for SARS-CoV-2

Intervention Type DIAGNOSTIC_TEST

* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR

1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test for SARS-CoV-2

* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR

1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Proven or suspected (not ruled out) SARS-CoV-2 infection (at the time of surgery)
* Undergoing urgent or emergency laparoscopic or open abdominal surgery
* Able to provide informed general consent on further use of clinical data

Exclusion Criteria

* Age \< 18 years
* Unable to provide informed general consent \& no possibility of informed general consent by proxy
* Recent (\<24h) negative test for SARS-CoV-2
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marco von Strauss und Torney

Role: PRINCIPAL_INVESTIGATOR

Clarunis University Centre for Gastrointestinal and Liver Diseases

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

052020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.